Sudeep Pharma Limited (NSE:SUDEEPPHRM)
India
· Delayed Price · Currency is INR 583.25
-1.40 (-0.24%)
At close: Mar 6, 2026
Sudeep Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2004 | 2003 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '04 Mar 31, 2004 | 2003 |
| Operating Revenue | 6,175 | 5,020 | 4,593 | 4,287 | 3,446 | 67.21 | Upgrade
|
| Other Revenue | - | - | - | - | - | 0.37 | Upgrade
|
| Revenue | 6,175 | 5,020 | 4,593 | 4,287 | 3,446 | 67.58 | Upgrade
|
| Revenue Growth (YoY) | 34.44% | 9.30% | 7.12% | 24.41% | 4999.06% | -5.85% | Upgrade
|
| Cost of Revenue | 2,261 | 1,677 | 1,676 | 1,868 | 1,376 | 59.58 | Upgrade
|
| Gross Profit | 3,914 | 3,343 | 2,917 | 2,420 | 2,070 | 8 | Upgrade
|
| Selling, General & Admin | 590.45 | 450.8 | 345.8 | 679.74 | 721.28 | - | Upgrade
|
| Other Operating Expenses | 1,142 | 992.44 | 751.74 | 831.86 | 660.83 | 0.64 | Upgrade
|
| Operating Expenses | 1,870 | 1,549 | 1,188 | 1,607 | 1,429 | 3.88 | Upgrade
|
| Operating Income | 2,044 | 1,794 | 1,729 | 812.88 | 640.66 | 4.12 | Upgrade
|
| Interest Expense | -66.28 | -54.59 | -38.2 | -45.82 | -14.69 | -2.32 | Upgrade
|
| Interest & Investment Income | 1.37 | 1.37 | 1.22 | 0.97 | 0.72 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 80.9 | 80.9 | 49.7 | 82.73 | 55.84 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 162.68 | -3.23 | 1.4 | 9.55 | -4.37 | -0.22 | Upgrade
|
| EBT Excluding Unusual Items | 2,222 | 1,818 | 1,744 | 860.31 | 678.16 | 1.58 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.09 | 0.09 | 0.94 | 0.33 | 0.51 | 0.05 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.41 | -0.41 | 0.02 | -0.84 | -0.03 | - | Upgrade
|
| Other Unusual Items | 8.41 | 8.41 | - | - | - | - | Upgrade
|
| Pretax Income | 2,232 | 1,828 | 1,748 | 859.8 | 685.35 | 1.63 | Upgrade
|
| Income Tax Expense | 533.03 | 441.16 | 416.08 | 236.59 | 187.36 | 0.26 | Upgrade
|
| Net Income | 1,682 | 1,387 | 1,332 | 623.21 | 497.99 | 1.38 | Upgrade
|
| Net Income to Common | 1,682 | 1,387 | 1,332 | 623.21 | 497.99 | 1.38 | Upgrade
|
| Net Income Growth | 26.27% | 4.14% | 113.75% | 25.14% | 36106.24% | -56.05% | Upgrade
|
| Shares Outstanding (Basic) | 109 | 109 | 109 | 109 | 109 | 24 | Upgrade
|
| Shares Outstanding (Diluted) | 109 | 109 | 109 | 109 | 109 | 24 | Upgrade
|
| Shares Change (YoY) | 0.70% | - | - | - | 361.48% | - | Upgrade
|
| EPS (Basic) | 15.40 | 12.79 | 12.28 | 5.74 | 4.59 | 0.06 | Upgrade
|
| EPS (Diluted) | 15.40 | 12.79 | 12.28 | 5.74 | 4.59 | 0.06 | Upgrade
|
| EPS Growth | 25.39% | 4.14% | 113.89% | 25.06% | 7745.71% | - | Upgrade
|
| Free Cash Flow | - | -155.06 | 157 | 12.42 | -603.93 | - | Upgrade
|
| Free Cash Flow Per Share | - | -1.43 | 1.45 | 0.11 | -5.57 | - | Upgrade
|
| Gross Margin | 63.38% | 66.60% | 63.52% | 56.44% | 60.06% | 11.84% | Upgrade
|
| Operating Margin | 33.10% | 35.74% | 37.66% | 18.96% | 18.59% | 6.10% | Upgrade
|
| Profit Margin | 27.24% | 27.63% | 29.00% | 14.54% | 14.45% | 2.04% | Upgrade
|
| Free Cash Flow Margin | - | -3.09% | 3.42% | 0.29% | -17.52% | - | Upgrade
|
| EBITDA | 2,191 | 1,891 | 1,813 | 887.29 | 685.36 | 7.36 | Upgrade
|
| EBITDA Margin | 35.48% | 37.66% | 39.48% | 20.70% | 19.89% | 10.90% | Upgrade
|
| D&A For EBITDA | 147.3 | 96.58 | 83.92 | 74.41 | 44.7 | 3.24 | Upgrade
|
| EBIT | 2,044 | 1,794 | 1,729 | 812.88 | 640.66 | 4.12 | Upgrade
|
| EBIT Margin | 33.10% | 35.74% | 37.66% | 18.96% | 18.59% | 6.10% | Upgrade
|
| Effective Tax Rate | 23.88% | 24.13% | 23.80% | 27.52% | 27.34% | 15.74% | Upgrade
|
| Revenue as Reported | 6,434 | 5,113 | 4,654 | 4,383 | 3,510 | 69.01 | Upgrade
|
| Advertising Expenses | - | 34.21 | 24.76 | 9.41 | 4.57 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.